Method for predicting responsiveness to plk1 inhibition
AssigneeNational University of Singapore
InventorsAnand Devaprasath JEYASEKHARAN, Sai Srinivas UPADHYAYULA, Mai Phuong HOANG, Michal Marek HOPPE
Life of this patent
Estimating the term…
Abstract
The present disclosure teaches a method of predicting the responsiveness of a subject towards a Polo-like kinase 1 (PLK1) inhibiting therapy. In one embodiment, there is provided a method for predicting the responsiveness of a subject towards a Polo-like kinase 1 (PLK1) inhibiting therapy, the method comprising determining the level and/or activity of AT-rich interacting domain 1A (ARID1A) in a sample obtained from the subject.
Claims12
A method for predicting the responsiveness of a subject towards a Polo-like kinase 1 (PLK1) inhibiting therapy, the method comprising determining the level and/or activity of AT-rich interacting domain 1A (ARID1A) in a sample obtained from the subject.
A method for predicting the responsiveness of a subject towards a Polo-like kinase 1 (PLK1) inhibiting therapy, the method comprising determining the mutation status of AT-rich interacting domain 1A (ARID1A) in a sample obtained from the subject.
A method for predicting the responsiveness of a subject towards a Polo-like kinase 1 (PLK1) inhibiting therapy, the method comprising determining transcriptomic and/or metabolic changes due to AT-rich interacting domain 1A (ARID1A) mutation(s) or loss in a sample obtained from the subject.
-14. (canceled)
Dependencies are inferred from the claim text.